Long-Term Results of Wegovy: ​​Latest Findings from the SELECT Trial!

Video will be live on Monday, July 8 at 1:00 PM Central Time. 

▪️ Join my channel to get access to perks! 
▪️ Download my FREE 7-Day Best Weight Journal here.  
▪️ Subscribe to my YouTube channel here.   

A recent study published in May 2024 unveiled a long-term outcome of Semaglutide, known as Wegovy or Ozempic. This builds on the SELECT trial, which showed Wegovy could reduce major cardiovascular events by 20% in individuals with obesity and no diabetes. Conducted by Ryan et al., the study followed participants for 208 weeks, or about four years.

The primary finding was not a new side effect but a continuation of Wegovy’s benefits. Participants experienced an average weight loss of about 10%, maintained over the entire four-year period. Initially, participants lost weight until around week 65, then sustained this weight reduction for the remainder of the study.

The results are impressive. The weight loss was not just temporary but sustained throughout the study’s duration. This stability contrasts with other long-term studies, such as those with Saxenda, where there is a tendency for weight regain over time. Wegovy’s ability to maintain weight loss over four years underscores its potential as a long-term weight management solution.

Regarding actual side effects, the study found no new or alarming issues. There were no new cases of cancers or other unusual conditions. About 17% of participants stopped taking Wegovy due to gastrointestinal side effects, aligning with other studies of GLP-1 medications. This finding supports the overall safety and effectiveness of Wegovy for long-term use.

In summary, this research highlights that the long-term “side effect” of Wegovy is a continued benefit: sustained weight loss over four years. This study reinforces the drug’s role in effective and durable weight management.

Thanks for watching and always remember: small tweaks lead to massive peaks! 

References: Ryan, D.H., Lingvay, I., Deanfield, J. et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med (2024). https://doi.org/10.1038/s41591-024-02996-7

Don’t forget to hit the subscribe button for more insightful content, and consider joining our YouTube Members Membership for exclusive benefits and monthly live sessions. 

Watch my previous videos to learn how to fight obesity and about the best medicine for weight loss: 
▪️ Watch This Before Taking Mounjaro  
▪️ From Ozempic to Mounjaro 
▪️ Muscle Loss with Ozempic, Wegovy & Mounjaro 
▪️ Managing Nausea from Ozempic, Wegovy and Trulicity!  
▪️ Ozempic: Stomach Paralysis Update  
▪️ How to Switch from Ozempic (or Wegovy) to Mounjaro  
▪️ Ozempic Paralyzed My Stomach 
▪️ How to Inject Mounjaro: step-by-step tutorial

Live in Alberta? Come see me at my Pharmacist-led Obesity Clinic at Apothecare Pharmacy – http://apothecarerx.ca 

Products I recommend to support your weight-loss journey: 
▪️ Managing Constipation 
▪️ Managing Diarrhea 
▪️ Managing Heartburn 
▪️ Internalized Weight Bias 
▪️ Protein Bars
▪️ Scales and More 
▪️ Supplements 
▪️ Activity Trackers  
▪️ My favorite Books 

– 

Dr. Dan

Follow me on social media for regular updates – @TheOfficialDrDan

Subscribe to my newsletter for a heads-up on all new content.

Sharing is caring! Here’s the social, email, and even text link –
https://healthevolved.co/long-term-wegovy

If you need some coaching support on your weight management journey, you can book a consultation with me to see if you’d be a good fit for our program. 

Questions or comments? Please send them my way on our Contact Us page!

Share:

More Posts

Orforglipron: A Diabetes Game Changer Hidden in Plain Sight

Orforglipron is a once-daily oral GLP-1 medication showing powerful results for people with type 2 diabetes. It lowers A1C and supports significant weight loss—all without injections, food restrictions, or lifestyle coaching. Based on the ACHIEVE-1 trial, this treatment could change how early type 2 diabetes is managed.

Peripheral Artery Disease (PAD) & Semglutide

If walking causes burning or cramping in your legs, it could be more than just aging or being out of shape—it might be Peripheral Artery Disease (PAD). Learn how semaglutide, commonly known for weight loss and diabetes, is now showing promise in improving mobility and reducing leg pain by improving blood flow.

CagriSema vs Tirzepatide

CagriSema and Tirzepatide are two of the most talked-about names in obesity treatment—now see how they compare. Explore the latest clinical results, real-world impacts, and what sets each medication apart when it comes to weight loss and metabolic health.

Mazdutide: China’s GLP-1 Gamechanger

Mazdutide is a new GLP-1/glucagon receptor agonist from China, showing promising weight loss results in recent trials. With up to 14% reduction in a lower-BMI population, it raises key questions about how it compares to Wegovy, Zepbound, and the future of obesity treatment.

Send Us A Message

Try My New Calorie Calculator!

Calculate your daily calorie and protein targets to help you achieve your weight goals.

Try My New Calorie Calculator!

Calculate your daily calorie and protein targets to help you achieve your weight goals.